These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29561464)

  • 41. Primary Hepatocellular Carcinoma With Intense 68Ga-PSMA Uptake But Slight 18F-FDG Uptake on PET/CT Imaging.
    Erhamamci S; Aslan N
    Clin Nucl Med; 2020 Mar; 45(3):e176-e177. PubMed ID: 31977478
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 68Ga-DOTATATE and 18F-FDG in Castleman Disease.
    Verçosa AFA; Flamini MEDM; Loureiro LVM; Flamini RC
    Clin Nucl Med; 2020 Nov; 45(11):868-870. PubMed ID: 32969902
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma.
    Trojan J; Schroeder O; Raedle J; Baum RP; Herrmann G; Jacobi V; Zeuzem S
    Am J Gastroenterol; 1999 Nov; 94(11):3314-9. PubMed ID: 10566736
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differentiation of Malignant Thrombus From Bland Thrombus of the Portal Vein in Patient With Hepatocellular Carcinoma on 18F-FDG PET CT.
    Agarwal KK; Shah D; Shah N; Mayank M
    Clin Nucl Med; 2017 Nov; 42(11):e472-e474. PubMed ID: 28922192
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [A case report of surgical treatment for hepatocellular carcinoma with a Hugely swollen lymph node that showed high FDG uptake].
    Hatano H; Masuike Y; Noda T; Tanida T; Oshima K; Komori T; Imamura H; Morita S; Iwazawa T; Akagi K; Yasumoto T; Adachi S; Dono K
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2133-5. PubMed ID: 25731447
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of metabolic characteristics and viability of lipiodolized hepatocellular carcinomas using 18F-FDG PET/CT.
    Kim HO; Kim JS; Shin YM; Ryu JS; Lee YS; Lee SG
    J Nucl Med; 2010 Dec; 51(12):1849-56. PubMed ID: 21098794
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Coexistence of primary hepatic myopericytoma and mediastinal Castleman disease in one patient: an interesting 18F-FDG PET/CT imaging case.
    Ma GY; Guan ZW
    Chin Med J (Engl); 2021 Sep; 134(20):2498-2499. PubMed ID: 34561326
    [No Abstract]   [Full Text] [Related]  

  • 48. Low glucose metabolism in hepatocellular carcinoma with GPC3 expression.
    Li YC; Yang CS; Zhou WL; Li HS; Han YJ; Wang QS; Wu HB
    World J Gastroenterol; 2018 Jan; 24(4):494-503. PubMed ID: 29398870
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictability of preoperative 18F-FDG PET for histopathological differentiation and early recurrence of primary malignant intrahepatic tumors.
    Song JY; Lee YN; Kim YS; Kim SG; Jin SJ; Park JM; Choi GS; Chung JC; Lee MH; Cho YH; Choi MH; Kim DC; Choi HJ; Moon JH; Lee SH; Jeong SW; Jang JY; Kim HS; Kim BS
    Nucl Med Commun; 2015 Apr; 36(4):319-27. PubMed ID: 25564069
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 18F-FDG PET for hepatocellular carcinoma presenting with portal vein tumor thrombus.
    Hanajiri K; Mitsui H; Maruyama T; Kondo Y; Shiina S; Omata M; Nakagawa K
    J Gastroenterol; 2005 Oct; 40(10):1005-6. PubMed ID: 16261443
    [No Abstract]   [Full Text] [Related]  

  • 51. Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment.
    Yamashige D; Kawamura Y; Kobayashi M; Shindoh J; Kobayashi Y; Okubo S; Muraishi N; Kajiwara A; Iritani S; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Kumada H
    Oncology; 2021; 99(3):169-176. PubMed ID: 33207358
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FDG-PET predicted unfavorable tumor histology in living donor liver transplant recipients; a retrospective cohort study.
    Ling LL; Hsu CC; Yong CC; Elsarawy AM; Chan YC; Wang CC; Li WF; Lin TL; Kuo FY; Cheng YF; Lin LM; Chen CL; Lin CC
    Int J Surg; 2019 Sep; 69():124-131. PubMed ID: 31386913
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictive value of ¹⁸F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma.
    Song MJ; Bae SH; Yoo IeR; Park CH; Jang JW; Chun HJ; Choi BG; Lee HG; Choi JY; Yoon SK
    World J Gastroenterol; 2012 Jul; 18(25):3215-22. PubMed ID: 22783045
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 18F-FDG PET CT as a prognostic factor in hepatocellular carcinoma.
    Cho E; Jun CH; Kim BS; Son DJ; Choi WS; Choi SK
    Turk J Gastroenterol; 2015 Jul; 26(4):344-50. PubMed ID: 26039005
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Castleman disease presenting with jaundice: a case with the multicentric hyaline vascular variant.
    Park JB; Hwang JH; Kim H; Choe HS; Kim YK; Kim HB; Bang SM
    Korean J Intern Med; 2007 Jun; 22(2):113-7. PubMed ID: 17616028
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preoperative prediction of microvascular invasion of hepatocellular carcinoma using
    Hyun SH; Eo JS; Song BI; Lee JW; Na SJ; Hong IK; Oh JK; Chung YA; Kim TS; Yun M
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):720-726. PubMed ID: 29167923
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A huge retroperitoneal Castleman's disease - rare entity.
    Jaishanker S; D'Cruze L; Muralidharan S; Gunabooshanam B; Singh KB
    J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S980-S982. PubMed ID: 38384096
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prediction of Posttransplantation Recurrence of Hepatocellular Carcinoma Using Metabolic and Volumetric Indices of 18F-FDG PET/CT.
    Kim YI; Paeng JC; Cheon GJ; Suh KS; Lee DS; Chung JK; Kang KW
    J Nucl Med; 2016 Jul; 57(7):1045-51. PubMed ID: 26985057
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Extrahepatic metastases of hepatocellular carcinoma on
    Sarma M; Padma S; Pavithran P; Somasundaram VH; Sundaram PS
    J Egypt Natl Canc Inst; 2021 Nov; 33(1):36. PubMed ID: 34825288
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cancer Metabolism as a Mechanism of Treatment Resistance and Potential Therapeutic Target in Hepatocellular Carcinoma.
    Lee M; Ko H; Yun M
    Yonsei Med J; 2018 Dec; 59(10):1143-1149. PubMed ID: 30450847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.